---
title: "Community Support Intervention for Driving Cessation Post-Acquired Brain Injury in Japan"
id: "plos-one-8-study-protocol-for-a-non-randomized-trial-of-community-participation-support"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-8-study-protocol-for-a-non-randomized-trial-of-community-participation-support"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362487"
published_at: "2026-11-10T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Community Support Intervention for Driving Cessation Post-Acquired Brain Injury in Japan
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-8-study-protocol-for-a-non-randomized-trial-of-community-participation-support
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362487)
- **Published At:** 2026-11-10T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Study protocol evaluates community participation support for individuals with **Acquired Brain Injury** (ABI) post-driving cessation in Japan. - Non-randomized trial involves ward-level allocation at a rehabilitation hospital. - Intervention group receives the **Community Life Support Program for Individuals with Acquired Brain Injury after Driving Cessation (CLASP-AID)**, while the control group receives usual care. - Primary outcome measured by the **Canadian Occupational Performance Measure (COPM)**, focusing on post-intervention performance scores. - Secondary outcomes assess quality of life, mobility readiness, and depressive symptoms. - The study aims to explore structured support's effectiveness in enhancing occupational performance and community integration post-driving cessation. Further evaluations post-discharge will track changes over time.
## Clinical Analysis & Structured Key Points
Study protocol for a non-randomized trial of community participation support for people with Acquired Brain Injury who have ceased driving in Japan | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Introduction Driving cessation after acquired brain injury (ABI) represents a major life transition that can restrict community participation and negatively affect quality of life. Although many individuals are unable to resume driving after illness or injury, structured support programs addressing life after driving cessation remain limited, and prospective evaluations are scarce. This study protocol describes a theoretically grounded community life support program for individuals with ABI who have ceased driving. Methods This is a single-center, non-randomized controlled trial with ward-level cluster allocation conducted in a convalescent rehabilitation hospital in Japan. Participants with ABI who were determined to be unable to resume driving will be allocated at the ward level to either an intervention group receiving the Community Life Support Program for Individuals with Acquired Brain Injury after Driving Cessation (CLASP-AID) or a control group receiving usual care. CLASP-AID is a participant-centered program based on a person–occupation–environment framework and includes structured educational sessions for individuals and, when applicable, family members, information on alternative transportation, and training with alternative mobility devices. The primary outcome is occupational performance assessed using the Canadian Occupational Performance Measure, with the primary endpoint defined as the post-intervention COPM performance score. Secondary outcomes include readiness for mobility transition, health-related quality of life, depressive symptoms, environmental factors, and life-space mobility. The COPM, ARMT-J, SF-12, GDS-15, CEQ, and LSA will be assessed at baseline and post-intervention. When feasible, follow-up assessments will also be conducted at 1, 3, and 6 months after discharge to explore changes over time. LSA findings will be treated as exploratory because the baseline and post-intervention assessments are conducted during hospitalization and may be influenced by restrictions in life-space mobility associated with the inpatient environment. Discussion This study will provide insight into the potential associations of a structured, occupation-focused support program for individuals with ABI after driving cessation. The findings are expected to inform future intervention development and contribute to evidence-based strategies for supporting community participation following driving cessation. Citation: Nasu S, Ishibashi Y, Sasaki T, Kobayashi R (2026) Study protocol for a non-randomized trial of community participation support for people with Acquired Brain Injury who have ceased driving in Japan. PLoS One 21(11): e0362487. https://doi.org/10.1371/journal.pone.0362487 Editor: Divakar Sharma, Lady Hardinge Medical College, INDIA Received: May 23, 2026; Accepted: October 23, 2026; Published: November 10, 2026 Copyright: © 2026 Nasu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion. Funding: SN received funding from the Toyota Foundation ( https://www.toyotafound.or.jp/english/ ) under the 2023 Research Grant Program (Grant Number: D23-R-0043) and from the Japan Society for the Promotion of Science (JSPS; https://www.jsps.go.jp/english/ ) through KAKENHI Grant-in-Aid for Research Activity Start-up (Grant Number: 24K23687). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. 1 Introduction Japan has experienced rapid population aging, with the proportion of older adults reaching a record high of approximately 29% [ 1 ]. Against this demographic background, stroke remains an important health concern in Japan, and cerebrovascular diseases, including stroke, are among the leading causes of death nationwide [ 2 ]. Stroke is known to cause a wide range of impairments, including physical, cognitive, sensory, and psychological impairments [ 3 ], which can result in substantial difficulties in daily life. Against this background, rehabilitation medicine has increasingly focused on automobile driving support for people after stroke. A domestic survey of 525 stroke survivors reported that approximately 70% wished to resume driving at the time of hospital discharge [ 4 ]; A multicenter questionnaire survey of individuals with brain injury in Japan reported that approximately 58% had resumed driving, indicating that approximately 42% had not resumed driving at the time of the survey [ 5 ]. Previous studies have suggested that inability to resume driving after acquired brain injury is associated with reduced community participation and restricted life-space mobility [ 6 ], as well as depressive tendencies [ 7 ]. Furthermore, qualitative research indicates that for some individuals, the inability to resume driving is perceived not merely as a restriction on mobility but as a loss of independence and future life roles [ 8 – 10 ]. Such perceptions may influence psychological reactions following driving cessation, as well as how individuals receive and engage with support. Recognizing these responses is clinically important, as support following driving cessation may need to address not only practical mobility challenges but also emotional and cognitive reactions that shape how individuals envision their future lives. At the same time, supporting adaptation after driving cessation does not necessarily require abandoning aspirations for future driving resumption. Rather, maintaining meaningful daily activities and social participation may help preserve motivation, health, and a sense of possibility during this transitional period. A pilot study of individuals who had ceased driving after acquired brain injury found reductions in participation in desired and necessary activities among those whose driving cessation had been decided by healthcare professionals or family members [ 11 ]. Together, these findings indicate that experiences following driving cessation, particularly continued engagement in meaningful activities regardless of subsequent driving outcomes, may be important considerations when designing support strategies for individuals with acquired brain injury. To inform the design of a driving cessation support program, we integrated findings from qualitative studies of individuals with acquired brain injury who had ceased driving and adopted the Person–Environment–Occupation model [ 12 ], a widely used framework in occupational therapy, to construct a middle-range theoretical framework [ 13 ]. In this framework, the “person” includes not only the individual who has ceased driving but also family members and close relatives who provide support. After driving cessation, community mobility often becomes difficult, and individuals frequently rely on family members for transportation. However, repeated requests for assistance may impose a burden on both the individual and family members, highlighting the importance of considering family involvement in post–driving cessation support [ 14 , 15 ]. The “occupation” component focuses on the meaning, role, and value that driving held for the individual. Identifying activities that have become difficult due to driving cessation and exploring alternative ways to continue these activities are considered essential [ 16 ]. The “environment” includes available public resources, alternative transportation options, services, and social supports. By individually examining which environmental resources can be utilized, support for individuals who have ceased driving may be more appropriately tailored [ 17 ]. To address this aim, we developed a participant-centered community life support program, the Community Life Support Program for Individuals with Acquired Brain Injury after Driving Cessation (CLASP-AID), based on a person–occupation–environment framework. We hypothesize that participation in the CLASP-AID program will be associated with greater readiness for driving cessation and higher levels of performance in necessary post-discharge activities compared with usual care, which was selected as the comparator to evaluate the added value of a structured, occupation-centered program beyond existing rehabilitation support. 2 Participant selection 2.1 Target population Participants will be individuals with acquired brain injury who are admitted to or attending outpatient services at a convalescent rehabilitation center in Shizuoka Prefecture, Japan, and who have undergone a driving assessment and been determined unable to resume automobile driving. The target population includes individuals aged 55 years or older, based on the age criteria used in previous studies of the Japanese version of the Assessment of Readiness for Mobility Transition (ARMT-J) [ 18 ]. 2.2 Inclusion criteria Participants must meet all of the following criteria: 1) Be aged 55 years or older. 2) Provide written informed consent after receiving sufficient explanation of the study and demonstrate sufficient cognitive ability to understand the study procedures and complete the study questionnaires and interviews 3) Have ceased driving with a standard automobile driver’s license. 4) Be independent in basic activities of daily living at the time of enrollment. 2.3 Exclusion criteria Participants will be excluded if any of the following apply: 1) Presence of conditions defined by the Public Safety Commission as disqualifying for driving resumption, including epilepsy, schizophrenia, or dementia. 2) Evident cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score of 24 or lower [ 19 ]. 3) Aphasia that interferes with adequate understanding of study procedures and assessments. 2.4 Recruitment Potential participants will be identified among inpatients and outpatients undergoing driving assessment at the study institution. Eligible individuals will be identified by the occupational therapist in charge of driving assessment, and invited to participate promptly after the attending physician and occupational therapist determine that driving cannot currently be safely resumed because of illness-related impairments. This determination follows the clinical driving assessment process and, in most cases, is made after the practical driving assessment. Written informed consent will be obtained before enrolment, baseline research assessment, and delivery of the study intervention, as described in Section 4 . To enhance questionnaire response rates, reminder contacts will be made by research staff when questionnaires are not returned within the expected timeframe. As of August 16, 2026, 27 participants had been enrolled, including 10 participants in the control group and 17 participants in the intervention group. Participant recruitment began on November 16, 2024, and was completed on September 30, 2026. The final follow-up is scheduled to be completed by March 31, 2027. Clinical driving-assessment records will be reviewed to identify all individuals who underwent driving assessment during the recruitment period. Among those judged unable to resume driving at that time, study eligibility and subsequent enrolment will be ascertained using the criteria in Sects 2.2 and 2.3 . Individuals who did not undergo driving assessment are outside this record-based screening population. The results report will include a participant flow diagram showing the numbers assessed for eligibility, eligible, consented and enrolled, and reasons for non-enrolment where documented. Post-enrolment exclusions, withdrawals, assessment completion, and loss to follow-up will be reported by group, with reasons where documented. Questionnaire return or nonreturn will be recorded at each scheduled follow-up. Nonresponse will be distinguished from withdrawal of consent, as described in Sect 5.5 . Information that cannot be established from the available records will be identified as unavailable. 3 Sample size, data types and study settings 3.1 Sample size Because this is a pilot and exploratory study conducted at a single rehabilitation center with allocation determined by ward admission, the sample size was determined primarily on the basis of recruitment feasibility. A formal power calculation for the planned ANCOVA was not performed because reliable prior estimates of the intervention-specific between-group effect and the correlation between baseline and post-intervention COPM performance scores were not available. Based on the anticipated number of eligible patients at the study site, a target sample size of 30 participants with evaluable primary outcome data was planned. To account for incomplete assessments and loss to follow-up, up to 40 participants may be recruited. No fixed equal allocation between groups was assumed because group assignment is determined by ward admission. This sample size is not intended to provide definitive statistical power for establishing intervention effectiveness or for accounting statistically for ward-level clustering. The primary analysis will instead estimate the adjusted between-group difference in post-intervention COPM performance scores and its 95% confidence interval. The resulting estimates of effect magnitude, variability, recruitment, retention, and data completeness will be used to inform the design and formal sample size calculation of a future adequately powered trial. 3.2 Types of data and materials All data collected during the study will initially be recorded on paper-based case report forms and subsequently entered into a password-protected computer within the study institution for analysis. 3.3 Study setting The CLASP-AID program and related assessments will be conducted in the occupational therapy department of the JA Kyosai Nakaizu Rehabilitation Center. If alternative mobility devices are required as substitutes for automobile driving, evaluations and interventions will be performed using the institution’s on-site mobility training course. Final evaluation of alternative mobility device use will be conducted with support from specialized external providers. When applicable, the Wheelchair Competency Test (WCT) will be used as a standardized assessment to support the evaluation process. 4 Informed consent The study explanation and consent process will begin promptly after the attending physician and occupational therapist determine that driving cannot currently be safely resumed because of illness-related impairments. This determination is based on routine clinical driving assessments, including desk-based, driving simulator, and practical driving assessments, and is made after the practical driving assessment in most cases. It concerns the participant’s current ability to resume driving, rather than necessarily indicating permanent driving cessation. Written informed consent will be obtained from all participants before enrolment, baseline research assessment, and delivery of the study intervention. An occupational therapist will review the ethics committee-approved participant information and consent documents ( S4 and S5 Files ) together with the individual, provide oral explanations, and confirm the individual’s willingness to participate. These explanations include the research use of routine clinical assessment results, including the inpatient COPM. Eligibility requires sufficient cognitive ability to understand the study procedures and complete the assessments, as specified in Sections 2.2 and 2.3 . Participants will be informed that participation is voluntary and that refusal or withdrawal will not result in any disadvantage. If new information arises that may affect a participant’s decision to continue in the study, or if the study protocol is modified, participants will be promptly informed. Revised consent documents will be approved by the ethics committee, and re-consent will be obtained as necessary. Oral explanations will be documented in the medical record, including the date, method of explanation, personnel involved, and the participant’s decision. 5 Materials and methods 5.1 Ethics approval The original ethics application was submitted to the Institutional Ethics Committee of Nakaizu Rehabilitation Center on August 6, 2024, and approved on October 1, 2024. Although the planned study period was scheduled to begin on September 1, 2024, no participants were enrolled and no study-related data were collected before ethics approval. The first participant was enrolled on November 16, 2024. The current protocol (version 1.0, dated January 16, 2026) was subsequently approved by the same committee (Approval No. 社中総発第77号). Written informed consent was obtained from all participants before enrollment. 5.2 Trial registration This trial was retrospectively registered with the UMIN Clinical Trials Registry on March 25, 2025 (UMIN000057350). The first participant was enrolled on November 16, 2024. The research team had initiated the registration process before participant recruitment and believed that all required registration procedures had been completed. However, it was subsequently identified that the registration had not been finalized and publicly disclosed. Once this was recognized, the remaining procedures were completed promptly. Participant recruitment began on November 16, 2024, and was completed on September 30, 2026. The final follow-up is scheduled to be completed by March 31, 2027. The authors confirm that all ongoing and related trials for this intervention are registered. 5.3 Study design and intervention 5.3.1 Study design. This study is a single-center, non-randomized controlled trial with a cluster allocation design. Participants will be assigned to either an intervention group (Group A) or a control group (Group B) based on ward-level allocation. The intervention group will receive the Community Life Support Program for Individuals with Acquired Brain Injury after Driving Cessation (CLASP-AID), while the control group will receive usual care. Because this study is conducted in a post-acute inpatient rehabilitation hospital in Japan, complete randomization and blinding are not feasible. To minimize contamination between groups, allocation will be performed at the ward level, with one ward assigned to the intervention group and another to the control group. This study involves no invasive procedures. This exploratory study will estimate between-group differences in outcomes. Because allocation is non-randomized and determined by ward admission, these differences may reflect both the intervention and differences in patient characteristics or ward-level care. Baseline characteristics will be summarized by group to describe potential imbalances arising from the non-randomized allocation. 5.3.2 Allocation. Participants admitted to the second-floor ward will be assigned to the control group, whereas those admitted to the third-floor ward will be assigned to the intervention group. Admission to the second- or third-floor ward is determined by a nurse-led team responsible for ward management, based on bed availability and the balance of patients’ clinical conditions across the wards. The investigators do not determine or alter ward placement for study group allocation. Ward admissi
## Related Clinical Research

- [Spreading depolarization alters distant cortical connectivity after focal injury](https://medichelpline.com/clinical-feed/plos-one-10-spreading-depolarization-drives-distant-connectivity-changes-in-the-focally.md)
- [EEG-derived indices classify sporadic Creutzfeldt-Jakob disease from Alzheimer’s and healthy aging](https://medichelpline.com/clinical-feed/plos-one-17-classification-of-sporadic-creutzfeldt-jakob-disease-based-on-resting-state.md)
- [NeuroSim: Multi-disorder EEG Simulator for Personalized Pattern Injection and AI Modeling](https://medichelpline.com/clinical-feed/biorxiv-5-neurosim-a-clinically-informed-multi-disorder-eeg-simulator-with-personalized.md)
- [Large Language Models in Clinical Neurology: Scoping Review of Performance and Safety](https://medichelpline.com/clinical-feed/pubmed-43056665.md) (DOI: 10.1212/CPJ.0000000000200687)
- [Timing of First Poststroke Seizure and Risk of Recurrence by Stroke Subtype](https://medichelpline.com/clinical-feed/medrxiv-3-timing-of-first-poststroke-seizure-and-risk-of-seizure-recurrence-by-stroke.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.